

Zealand announces the total number of shares and voting rights in the company as of 30 June 2016

Copenhagen, 30 June 2016 - In accordance with Section 6 of the *Danish Statutory Order on Issuers' Disclosure Obligations*, Zealand issues announcements to inform of the total number of shares and voting rights in the company at the end of a calendar month in which there have been changes to its share capital.

In company announcement no. 25 / 2016 dated 16 June 2016, Zealand announced an increase in its share capital and voting rights after exercises of employee warrants. Following from this announcement, the table below lists the total number of shares and voting rights in Zealand as of 30 June 2016.

Date	Number of shares (nominal value of DKK 1 each)	Share capital (nominal value in DKK)	Number of votes rights
30 June 2016	24,534,175	24,534,175	24,534,175



For further information, please contact:

Hanne Leth Hillman, Senior Vice President, Investor Relations and Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a pipeline of proprietary drug candidates which primarily target specialty disease areas with significant unmet medical needs and a portfolio of medicines and product candidates under license collaborations with Sanofi, Helsinn and Boehringer Ingelheim.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed globally outside the United States as Lyxumia[®] and is under regulatory review in the United States. A fixed-ratio combination of lixisenatide with basal insulin glargine (Lantus[®]), referred to as iGlarLixi, is under regulatory review in the United States and in Europe.

The proprietary pipeline of drug candidates includes: *ZP4207* (single-dose glucagon rescue treatment) for acute, severe hypoglycemia (Phase II); *ZP1848* for short bowel syndrome (Phase II); *ZP4207* (multiple-dose glucagon), intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (in preparation for Phase II); *ZP2929* for diabetes/obesity (Phase I); and several preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about its business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.